From Nodal Metastasis to Oncologic Recurrence in Tongue and Oral Floor Squamous Cell Carcinoma: Distinct Failure Patterns and Clinicopathological Risk Profiles - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Patterns of Failure and Risk Profiles in Tongue and Oral Floor Squamous Cell Carcinoma: Insights from Nodal Metastasis to Oncologic Recurrence

  • By

  • Jannik Ketschau

  • Jonathan Mohr

  • Alex Grabenhorst

  • Hannes Singer

  • Helena Kram

  • Cornelius Leopold

  • Nils Krautkremer

  • Katharina Pippich

  • Klaus-Dietrich Wolff

  • Lucas M. Ritschl

  • June 9, 2026

Share

  • 1

    Oral squamous cell carcinoma (OSCC) treatment often involves surgical resection and elective cervical lymph node management.

  • 2

    Regional nodal recurrences in OSCC typically occur on the ipsilateral side, particularly involving level II lymph nodes.

  • 3

    Contralateral nodal recurrence is less common but may occur in advanced tongue and floor of mouth tumors.

  • 4

    The study analyzed predictors of nodal involvement and recurrence patterns in a cohort of 438 OSCC patients.

  • 5

    Clinicopathological factors may drive distinct patterns of local, ipsilateral, and contralateral nodal recurrences.

Original Source(s)

From Nodal Metastasis to Oncologic Recurrence in Tongue and Oral Floor Squamous Cell Carcinoma: Distinct Failure Patterns and Clinicopathological Risk Profiles

  • by Jannik Ketschau, Jonathan Mohr, Alex Grabenhorst, Hannes Singer, Helena Kram, Cornelius Leopold, Nils Krautkremer, Katharina Pippich, Klaus-Dietrich Wolff, Lucas M. Ritschl

  • June 9, 2026

Related Content

Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers

Comment on “Life’s essential 8 and specific cancer risk and mortality in men and women: a population-based cohort analysis of 332,417 United Kingdom participants” and the inclusion of sleep in cancer focused guidelines

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma